香港股市 將在 4 小時 50 分鐘 開市

Dr. Reddy's Laboratories Limited (DRREDDY.BO)

BSE - BSE 即時價格。貨幣為 INR。
加入追蹤清單
4,370.05+19.55 (+0.45%)
收市價: 03:29PM IST
全螢幕
前收市價4,350.50
開市4,324.85
買盤4,360.55 x 0
賣出價4,371.65 x 0
今日波幅4,298.60 - 4,376.90
52 週波幅2,497.60 - 5,514.65
成交量2,879
平均成交量49,937
市值724.987B
Beta 值 (5 年,每月)
市盈率 (最近 12 個月)38.90
每股盈利 (最近 12 個月)
業績公佈日2020年10月28日
遠期股息及收益率無 (無)
除息日
1 年預測目標價2,581.68
  • Insider Monkey

    Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2023 Earnings Call Transcript

    Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2023 Earnings Call Transcript January 25, 2023 Operator: Ladies and gentlemen, good day, and welcome to Dr. Reddy’s Laboratories Limited Q3 FY 2023 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions […]

  • Benzinga

    Intercept Settles Ocaliva Litigation With Reddy's Lab

    Intercept Pharmaceuticals Inc (NASDAQ: ICPT) and its subsidiary Intercept Pharma Europe Limited settled patent litigation with Dr. Reddy’s Laboratories Ltd (NYSE: RDY). The litigation concerns the submission by Dr. Reddy’s of an Abbreviated New Drug Application seeking approval to market a generic version of Ocaliva (obeticholic acid) 5 mg and 10 mg tablets before the expiration of the Company’s U.S. patents. Related: Intercept Shares Jump After Reissuing Annual Guidance. Under the terms of the

  • Benzinga

    Eton Pharma Shares Tick Higher After Offloading Hospital Products

    Eton Pharmaceuticals Inc (NASDAQ: ETON) has sold its hospital products to Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories Ltd (NYSE: RDY), for $50 million. "The sale of our hospital products allows us to focus our resources on our core rare disease business, which is rapidly growing, and also provides an attractive opportunity to monetize the value we have created with our hospital products," said CEO Sean Brynjelsen, CEO of Eton. Dr. Reddy's purchased the Biorphen, Rezipre